| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | FREQ | Stock Option (Right to Buy) | Award | +23.7K | 23.7K | Nov 3, 2023 | Common Stock | 23.7K | $21.94 | Direct | F1, F2, F3, F4 | |||
| transaction | FREQ | Stock Option (Right to Buy) | Award | $0 | +29.1K | $0.00 | 29.1K | Nov 3, 2023 | Common Stock | 29.1K | $14.98 | Direct | F5 |
| Id | Content |
|---|---|
| F1 | Under the terms of an Agreement and Plan of Merger dated as of July 14, 2023 by and among Korro Bio Ops, Inc. (f/k/a Korro Bio, Inc., "Legacy Korro"), the Issuer (f/k/a Frequency Therapeutics, Inc.) and Frequency Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), on November 3, 2023, Merger Sub merged with and into Legacy Korro (the "Merger"), with Legacy Korro surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Korro common stock issued under the Korro Bio, Inc. |
| F2 | (Continued from footnote 1) 2019 Stock Incentive Plan (the "2019 Plan") was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, at an exchange ratio of 0.049688 per share, on the same terms and conditions as were applicable under the 2019 Plan prior to the Merger, after giving effect to a reverse stock split of the Issuer's common stock of 1-for-50. Subsequent to the Merger, the name of the Issuer was changed from Frequency Therapeutics, Inc. to Korro Bio, Inc. |
| F3 | The shares subject to the option vest as to 25% of the shares on May 8, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |
| F4 | Received in exchange for a stock option to acquire 477,453 shares of Legacy Korro common stock issued under the 2019 Plan pursuant to the Merger Agreement. |
| F5 | The shares subject to the option vest in 48 equal monthly installments commencing from November 3, 2023, subject to the Reporting Person's continued service on each such vesting date. |
Senior Vice President, General Counsel and Secretary